Literature DB >> 11118182

"Extracts from "Clinical evidence": Menopausal symptoms.

J Rymer1, E P Morris.   

Abstract

DEFINITION: Menopause begins one year after the last menstrual period. Symptoms often begin in the perimenopausal years. INCIDENCE/PREVALENCE: In the United Kingdom the mean age for the menopause is 50 years 9 months. The median onset of the perimenopause is between 45.5 and 47.5 years. One Scottish survey (of 6096 women aged 45 to 54 years) found that 84% had experienced at least one of the classic menopausal symptoms, with 45% finding one or more symptoms a problem. AETIOLOGY/RISK FACTORS: Urogenital symptoms of menopause are caused by decreased oestrogen concentrations, but the cause of vasomotor symptoms and psychological effects is complex and remains unclear. PROGNOSIS: Menopause is a physiological event. Its timing may be genetically determined. Although endocrine changes are permanent, menopausal symptoms such as hot flushes, which are experienced by about 70% of women, usually resolve with time. However, some symptoms, such as genital atrophy, may remain the same or worsen. AIMS: To reduce or prevent menopausal symptoms, and to improve quality of life with minimum adverse effects. OUTCOMES: Frequency and severity of vasomotor, urogenital, and psychological symptoms; quality of life.
METHODS: Clinical Evidence search and appraisal December 1999. We included only randomised controlled trials (RCTs) and systematic reviews that met Clinical Evidence quality criteria.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11118182      PMCID: PMC1119220          DOI: 10.1136/bmj.321.7275.1516

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  41 in total

Review 1.  Livial: a review of clinical studies.

Authors:  R A Moore
Journal:  Br J Obstet Gynaecol       Date:  1999-03

2.  Treatment of menopausal hot flashes with transdermal administration of clonidine.

Authors:  M Nagamani; M E Kelver; E R Smith
Journal:  Am J Obstet Gynecol       Date:  1987-03       Impact factor: 8.661

3.  Use of medroxyprogesterone acetate to prevent menopausal symptoms.

Authors:  J L Bullock; F M Massey; R D Gambrell
Journal:  Obstet Gynecol       Date:  1975-08       Impact factor: 7.661

4.  Long term effects of tibolone on the genital tract in postmenopausal women.

Authors:  E P Morris; P O Wilson; J Robinson; J M Rymer
Journal:  Br J Obstet Gynaecol       Date:  1999-09

5.  Long-term placebo-controlled efficacy and safety study of Org OD 14 in climacteric women.

Authors:  L J Benedek-Jaszmann
Journal:  Maturitas       Date:  1987       Impact factor: 4.342

6.  Effect of oral medroxyprogesterone acetate on menopausal symptoms in patients with endometrial carcinoma.

Authors:  K Aslaksen; B Frankendal
Journal:  Acta Obstet Gynecol Scand       Date:  1982       Impact factor: 3.636

7.  Hormonal treatments of sexual unresponsiveness in postmenopausal women: a comparative study.

Authors:  M G Dow; D M Hart; C A Forrest
Journal:  Br J Obstet Gynaecol       Date:  1983-04

8.  Placebo-controlled cross-over study of effects of Org OD 14 in menopausal women.

Authors:  P M Kicovic; J Cortés-Prieto; M Luisi; S Milojevic; F Franchi
Journal:  Reproduccion       Date:  1982 Apr-Jun

9.  Clonidine (Dixarit) for menopausal flushing.

Authors:  R F Edington; J P Chagnon; W M Steinberg
Journal:  Can Med Assoc J       Date:  1980-07-05       Impact factor: 8.262

10.  Oral medroxyprogesterone in the treatment of postmenopausal symptoms.

Authors:  I Schiff; D Tulchinsky; D Cramer; K J Ryan
Journal:  JAMA       Date:  1980-09-26       Impact factor: 56.272

View more
  16 in total

Review 1.  Making decisions about hormone replacement therapy.

Authors:  Janice Rymer; Ruth Wilson; Karen Ballard
Journal:  BMJ       Date:  2003-02-08

2.  Women's quality of life in the premenopausal and postmenopausal periods.

Authors:  Sevgi Ozkan; Erkan S Alataş; Mehmet Zencir
Journal:  Qual Life Res       Date:  2005-10       Impact factor: 4.147

3.  Immunohistochemical analysis of collagen types I, III, IV and alpha-actin in the urethra of sexually intact and ovariectomized beagles.

Authors:  Heinz R Augsburger; Marianne Oswald
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2007-01-06

4.  Immunohistochemical analysis of estrogen receptors in the urethra of sexually intact, ovariectomized, and estrogen-substituted ovariectomized sheep.

Authors:  Heinz R Augsburger; Constanze Führer
Journal:  Int Urogynecol J       Date:  2013-12-07       Impact factor: 2.894

5.  A prospective study of hormone therapy and depression in community-dwelling elderly women: the Three City Study.

Authors:  Jacqueline Scali; Joanne Ryan; Isabelle Carrière; Jean-François Dartigues; Béatrice Tavernier; Karen Ritchie; Marie-Laure Ancelin
Journal:  J Clin Psychiatry       Date:  2010-08-10       Impact factor: 4.384

6.  Initiation and discontinuation of hormone therapy for menopausal symptoms: results from a community sample.

Authors:  Hayden B Bosworth; Lori A Bastian; Steven C Grambow; Colleen M McBride; Celette Sugg Skinner; Laura Fish; Barbara K Rimer; Ilene C Siegler
Journal:  J Behav Med       Date:  2005-02

7.  Factors influencing serum concentration of CA125 and CA15-3 in Iranian healthy postmenopausal women.

Authors:  Alamtaj Samsami Dehaghani; Alireza Fotouhi Ghiam; Marjan Hosseini; Sareh Mansouri; Abbas Ghaderi
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

8.  Quality of life in menopausal women: a Brazilian Portuguese version of the Cervantes Scale.

Authors:  José E M Lima; Santiago Palacios; Maria C O Wender
Journal:  ScientificWorldJournal       Date:  2012-03-12

9.  Relationships between menopausal syndrome and sleeping of middle-aged women.

Authors:  Yi Kyun Park; Nam Hyun Cha; Sohyune R Sok
Journal:  J Phys Ther Sci       Date:  2015-08-21

10.  Sleep disorders and depression due to menopausal symptoms in middle-aged Korean females.

Authors:  Kim Jin; Cha Nam Hyun
Journal:  J Phys Ther Sci       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.